SCHEMBL2344730

SCHEMBL2344730

CC(C)c1nc(NS(C)(=O)=O)nc(-c2ccc(F)cc2)c1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.37
PTGS1 P23219 3/20 0.37
ALOX5 P09917 1/20 0.37
SCN9A Q15858 3/20 0.35
TRPV1 Q8NER1 2/20 0.35
CXCR2 P25025 1/20 0.34
MAP2K4 P45985 1/20 0.33
ADORA1 P30542 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
NR3C2 P08235 1/20 0.33
AR P10275 1/20 0.33
KIT P10721 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2344282 0.90 ADORA1 (0.43) PTGS2PTGS1SCN9AADORA1
SCHEMBL2340376 0.84 ADORA2A (0.39) PTGS2PTGS1SCN9AADORA1
SCHEMBL2337795 0.82 GCGR (0.38) PTGS2PTGS1CXCR2
SCHEMBL2343663 0.82 PTGS2 (0.37) PTGS2PTGS1ADORA1
SCHEMBL2342269 0.80 HMGCR (0.51) PTGS2PTGS1
SCHEMBL17309549 0.79 ALOX5 (0.42) PTGS2PTGS1ALOX5SCN9ATRPV1
SCHEMBL2345988 0.78 ALOX5 (0.44) PTGS2PTGS1ALOX5SCN9ATRPV1
SCHEMBL2343451 0.78 ALOX5 (0.41) PTGS2PTGS1ALOX5SCN9ATRPV1
SCHEMBL2339952 0.78 ALOX5 (0.41) PTGS2PTGS1ALOX5SCN9ATRPV1
SCHEMBL22785825 0.77 GCGR (0.51) PTGS2PTGS1ALOX5SCN9ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361906-A1 Process for preparing rosuvastatin AstraZeneca UK Limited (GB) 2011-08-31 EP claimed
US-20080207903-A1 Chemical Process ASTRAZENECA UK LIMITED (GB) 2008-08-28 US claimed
EP-1871747-A2 PROCESS FOR PREPARING ROSUVASTATIN AstraZeneca UK Limited (GB) 2008-01-02 EP claimed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 WO claimed
US-8034932-B2 Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin ASTRAZENECA UK LIMITED (GB) 2011-10-11 US disclosed
EP-2361906-A1 Process for preparing rosuvastatin AstraZeneca UK Limited (GB) 2011-08-31 EP disclosed
US-20080207903-A1 Chemical Process ASTRAZENECA UK LIMITED (GB) 2008-08-28 US disclosed
EP-1871747-A2 PROCESS FOR PREPARING ROSUVASTATIN AstraZeneca UK Limited (GB) 2008-01-02 EP disclosed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207903-A1 Chemical Process CYP2C9, CYP2B6, CYP7A1 PTGS2 1670/4885PTGS1 1471/4885ALOX5 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.